FairJourney Bio opens US cryo-EM facility to accelerate antibody discovery

Published: 15-Apr-2026
Manufacturing

CRO FairJourney Bio has opened its advanced cryo-electron microscopy facility in San Diego, integrating atomic-resolution structural biology into its antibody discovery platform to speed up early-stage drug development

FairJourney Bio (FJBio) has announced the opening of its advanced cryo-electron microscopy (cryo-EM) structural biology facility in San Diego, California, incorporating atomic-resolution structural biology directly into its antibody discovery platform.

The firm said in a statement that the new site will "significantly [expand] the company's presence in the US market."

The facility features advanced 300 kV cryo-EM technology with two ThermoFisher Titan Krios 5 systems, enabling the determination of native-state antibody-target structures.

Launched in January 2026, these cryo-EM services represent a key advancement in FJBio's antibody discovery workflow.

They provide rapid, detailed structural insights within two to three weeks, enhancing the entire R&D value chain from epitope mapping to lead optimisation. Scientists can visualise protein structures at atomic resolution, delivering high-quality results to support informed decision-making across programmes.

Strategically located within a prominent biotech hub, the facility complements FJBio's existing presence in San Francisco and European operations.

"Structural biology has historically been a late-stage tool, used to confirm decisions already made," said Dr Christopher Arthur, Chief Scientific Officer, Structural Biology, FairJourney Bio.

"We are redefining that paradigm."

In San Diego, we are building a premier, full-service cryo-EM CRO that brings together decades of deep expertise in sample preparation, data collection and computational analysis, embedding structural insight at the very start of discovery, where it shapes epitope selection and determines which leads are worth advancing.

Dr Werner Lanthaler, CEO, FairJourney Bio, added: "We are at an exciting time for Cryo-EM-driven drug discovery, as we begin to recognise its potential to transform antibody discovery and development."

"It is a great honour that FJBio is globally leading this new wave of cutting-edge technology that will dramatically increase [the] probability of success, right from the very earliest stages of discovery."

With our new cryo-EM services, we will help our customers to significantly save time and costs and accelerate their workflows.

See more

You may also like

Media

Aragen launches ChemiSHE, India's first women-led chemistry synthesis laboratory

Read more
The firm has inaugurated ChemiSHE, a pioneering all-women chemistry synthesis laboratory at its Hyderabad campus, as part of a broader diversity initiative targeting the addition of up to 1000 women employees across scientific and leadership roles during the next three years

Trending Articles

  1. An integrated path: how CDMOs are reshaping complex drug development The pharmaceutical CDMO sector is rapidly evolving toward integrated, end-to-end partnerships that align development, manufacturing, packaging and supply to meet the growing complexity, cost pressures and scalability demands of advanced biologics and precision therapies
  2. ROIS CDMO closes on the acquisition of US Injectable Manufacturing Facility This strategic move establishes ROIS as a global Contract Development and Manufacturing Organisation (CDMO), expanding from its existing European operations to now offer US-based sterile production
  3. Swiss Rockets collaborates with Lonza to advance Torqur’s oncology drug candidate bimiralisib into late-stage clinical development Lonza to provide cGMP manufacturing and technical support to advance bimiralisib into late-stage clinical development
  4. ImmuneOncia Therapeutics and Lonza collaborate to manufacture Danburstotug Lonza to support development and manufacturing of ImmuneOncia’s Danburstotug with a complete and integrated end-to-end drug substance and drug product solution
  5. L.B. Bohle hosts successful continuous manufacturing workshop in Brazil Focus on continuous wet granulation and drying for research, development and small-scale production

Upcoming event

Making Pharmaceuticals

21–22 April 2026 | Exhibition | Coventry, UK See all

You may also like

Media

Aragen launches ChemiSHE, India's first women-led chemistry synthesis laboratory

The firm has inaugurated ChemiSHE, a pioneering all-women chemistry synthesis laboratory at its Hyderabad campus, as part of a broader diversity initiative targeting the addition of up to 1000 women employees across scientific and leadership roles during the next three years
Manufacturing

Why patient voices matter in rare disease innovation

Patient advocacy event highlights the role of collaboration and lived experience in advancing rare disease treatments
Manufacturing

How to build a defensible tech transfer for tablets and capsules

In tablet and capsule manufacturing, tech transfer is often treated as a documentation exercise when it is really a test of process understanding. That distinction matters
Manufacturing

Biopharma firms favour European contract manufacturing over US sites despite tariff pressure

US contract manufacturing deals for FDA-approved drugs hit a five-year low in 2025, as biopharma companies (including major US-headquartered firms) increasingly direct outsourced production to European facilities, new GlobalData analysis reveals
Manufacturing

Touchlight partners with SVF Vaccines to advance dual hepatitis B/D vaccine into clinical development

The pair will progress an innovative dual-targeting hepatitis B and D vaccine into clinical trials, leveraging Touchlight's enzymatic doggybone DNA platform, which has demonstrated significant dose-sparing potential compared to traditional plasmid DNA
Manufacturing

An integrated path: how CDMOs are reshaping complex drug development

The pharmaceutical CDMO sector is rapidly evolving toward integrated, end-to-end partnerships that align development, manufacturing, packaging and supply to meet the growing complexity, cost pressures and scalability demands of advanced biologics and precision therapies
Manufacturing

Pharmaceutical labelling in focus at Interpack 2026

Well prepared for new requirements. The upcoming reform of EU pharmaceutical legislation is expected to bring stricter requirements for traceability and labelling. The new 152E HC wrap-around labelling machine, developed specifically for contract packers, covers a wide product range with minimal change parts. Also on display: specialised labelling machines for automated product handling of small batches and high-speed labelling applications.
Subscribe now